We are live on ! Find out more
SNDX icon

Syndax Pharmaceuticals

139 hedge funds and large institutions have $1.44B invested in Syndax Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 61 increasing their positions, 28 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,129% more call options, than puts

Call options by funds: $5.43M | Put options by funds: $442K

118% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 28

117% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 12

67% more funds holding in top 10

Funds holding in top 10: 6 → 10 (+4)

64% more capital inflows, than outflows

Capital inflows: $222M | Capital outflows: $135M

15% more funds holding

Funds holding: 121 → 139 (+18)

7.66% more ownership

Funds ownership: 98.21% → 105.87% (+7.7%)

Holders
139
Holders Change
+18
Holders Change %
+14.88%
% of All Funds
2.38%
Holding in Top 10
10
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+66.67%
% of All Funds
0.17%
New
26
Increased
61
Reduced
28
Closed
12
Calls
$5.43​M
Puts
$442​K
Net Calls
+$4.99​M
Net Calls Change
+$1.53​M

SNDX Hedge Fund Activity: Q3 2022 in Review

139 of the 5,833 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q3 2022, worth a combined $1.44B — up 35% from $1.06B a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new SNDX positions and 12 closed out — a net gain of 14 holders — while 61 added to existing stakes and 28 trimmed.

The largest buyer was Jennison Associates, opening a new position worth an estimated $37M. The largest seller was Nantahala Capital Management, cutting an estimated $28.9M.

  • 139 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q3 2022, up from 121 in Q2 2022.
  • Funds reported $1.44B of Syndax Pharmaceuticals stock for Q3 2022, up 35% quarter-over-quarter.
  • 26 funds opened new Syndax Pharmaceuticals positions in Q3 2022 and 12 closed out, a net change of +14 holders.
  • The largest Syndax Pharmaceuticals buyer in Q3 2022 was Jennison Associates, an estimated $37M added.
  • The largest Syndax Pharmaceuticals seller in Q3 2022 was Nantahala Capital Management, an estimated $28.9M sold.

Based on aggregated 13F filings for Q3 2022.